Akums Drugs & Pharma

472.20
+11.95
(2.60%)
Market Cap
7,432.14 Cr
EPS
-0.28
PE Ratio
50.64
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,175.90
52 Week Low
432.60
PB Ratio
2.55
Debt to Equity
0.83
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy+100.00 %
+100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,723.90
#1 4,13,621.36
35.22
#1 49,887.20
12.06
#1 9,648
13.77
54.16
5,774.55
1,53,296.16
75.20
8,184.00
0.89
1,600
#1 64.53
56.90
1,450.85
1,17,172.81
24.00
26,520.70
14.17
4,155
47.38
51.80
3,213.10
1,08,745.90
58.64
10,785.70
11.59
1,656
13.54
59.74
2,422.90
99,963.65
49.78
10,615.60
19.57
1,942
-16.38
59.91
1,150.50
96,004.09
#1 18.06
28,905.40
12.36
5,578
1.69
47.74
2,000.00
91,308.19
32.14
20,141.50
#1 19.94
1,936
38.82
47.45
883.80
88,930.96
19.77
19,831.50
13.82
3,831
29.92
42.86
1,155.00
67,082.59
19.21
29,559.20
17.55
3,169
-10.04
53.81
30,760.95
65,364.87
48.70
6,097.20
10.80
1,201
16.01
55.29
Growth Rate
Revenue Growth
12.48 %
Net Income Growth
-99.18 %
Cash Flow Change
182.09 %
ROE
-99.19 %
ROCE
-97.66 %
EBITDA Margin (Avg.)
-63.65 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
978
1,188
1,093
955
1,026
1,050
1,030
Expenses
1,095
1,057
989
941
891
912
889
EBITDA
-117
131
103
14
135
138
141
Operating Profit %
-13 %
11 %
9 %
0 %
13 %
12 %
12 %
Depreciation
30
30
32
34
34
35
45
Interest
12
14
12
12
13
12
5
Profit Before Tax
-159
87
59
-33
88
92
91
Tax
29
54
-136
7
26
25
25
Net Profit
-187
33
195
-40
61
67
66
EPS in ₹
-13.16
2.22
13.21
-2.89
4.21
4.37
4.26

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
Total Assets
2,078
2,192
3,069
3,267
3,516
Fixed Assets
645
834
1,021
1,097
1,191
Current Assets
1,250
1,157
1,864
1,879
1,941
Capital Work in Progress
57
87
31
103
195
Investments
6
19
0
0
0
Other Assets
1,371
1,252
2,017
2,066
2,130
Total Liabilities
2,078
2,192
3,069
3,267
3,516
Current Liabilities
730
580
1,272
1,266
1,211
Non Current Liabilities
627
725
1,172
1,278
1,585
Total Equity
721
887
625
723
721
Reserve & Surplus
721
884
608
689
681
Share Capital
1
1
14
29
29

Cash Flow

Cash Flow
2015
2016
2020
2021
2022
2023
2024
Net Cash Flow
-11
4
71
-70
33
-4
59
Investing Activities
-150
-123
-190
-109
-235
-305
-331
Operating Activities
72
89
28
135
32
177
498
Financing Activities
66
37
233
-95
236
125
-108

Share Holding

% Holding
Feb 2024
Aug 2024
Sept 2024
Dec 2024
Promoter
84.91 %
75.26 %
75.26 %
75.26 %
FIIs
0.00 %
5.32 %
7.34 %
6.36 %
DIIs
0.00 %
7.60 %
7.52 %
7.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.43 %
2.11 %
3.33 %
Others
15.09 %
7.38 %
7.77 %
8.05 %
No of Share Holders
8
1,38,205
57,531
68,410

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Resignation Of Senior Management Personnel2 days ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report9 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of PatentFeb 14, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 11, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Statement Of Deviation.Feb 07, 2025
Integrated Filing (Financial)Feb 07, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 07, 2025
Un-Audited Financial Results For The Quarter And Nine Months Ended December 31 2024.Feb 07, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 06Th February 2025Feb 06, 2025
Announcement under Regulation 30 (LODR)-CessationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2025
Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2024.Feb 01, 2025
Update On Income Tax SearchJan 23, 2025
Income Tax SearchJan 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 11, 2025
Change Of Name Of RTAJan 02, 2025
Closure of Trading WindowDec 28, 2024
Shareholder Meeting / Postal Ballot-Scrutinizers ReportDec 17, 2024
Submission Of Additional Details As Per SEBI Circular No. SEBI/HO/CFD/Cfdpod-1/P/CIR/2023/123 Dated 13Th July 2023 On Our Disclosure Dated 19Th November, 24 On Execution Of Exclusive Master Sales Agreement With Caregen Co., Ltd.Nov 26, 2024
Akums Exclusively Ties Up With Jagdale For Marketing Of Ready-To-Drink Nutritional Beverages In Aseptic Carton TechnologyNov 26, 2024
Execution Of Exclusive Master Sales Agreement With Caregen Co., Ltd ('Caregen')Nov 19, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 15, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 15, 2024
Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 14, 2024
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 13, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 11, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 11, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 09, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 09, 2024
Statement Of Deviation And VariationNov 09, 2024
Outcome Of Board MeetingNov 09, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2024
Board Meeting Intimation for Un-Audited (Standalone & Consolidated) Financial Results For The Quarter And Half Year Ended On 30Th September, 2024.Nov 05, 2024
Intimation Of Execution Of Memorandum Of Understanding With 'The Government Of Republic Of Zambia' On Local Manufacturing Of MedicinesOct 18, 2024
Execution Of License & Distribution Agreement With Triple Hair Inc., CanadaOct 16, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 11, 2024
Launch Of Dual Action Heartburn Relief Chewable TabletOct 09, 2024
Announcement under Regulation 30 (LODR)-Credit RatingOct 09, 2024

Technical Indicators

RSI(14)
Neutral
34.59
ATR(14)
Volatile
25.53
STOCH(9,6)
Neutral
27.55
STOCH RSI(14)
Oversold
2.39
MACD(12,26)
Bearish
-2.19
ADX(14)
Weak Trend
22.78
UO(9)
Bearish
36.74
ROC(12)
Downtrend And Accelerating
-6.53
WillR(14)
Oversold
-81.56

About Akums Drugs & Pharma

Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and development, regulatory dossier preparation and filing, and testing services. Akums has manufacturing units accredited by global regulatory agencies and specializes in various therapeutic areas. The company has expanded through acquisitions and establishment of new facilities over the years. It operates in three main segments: CDMO, API, and Branded and Generic formulations. Akums has manufactured over 4,000 commercialized formulations across more than 60 dosage forms.
Listing Date
06 Aug, 2024(0 Years, 50 days)
Chairperson Name